PartnershipJul 14, 2026, 04:32 PM
West Pharma Renews Tech Exchange & Distribution Pacts with Daikyo
AI Summary
West Pharmaceutical Services, Inc. and Daikyo Seiko, Ltd. have entered into an Amended and Restated Technology Exchange and Crosslicense Agreement and two Distributorship Agreements, effective July 14, 2026. These agreements, largely similar to previous ones, facilitate technology sharing for pharmaceutical product components and establish distribution rights. West maintains a 49% ownership in Daikyo, and all agreements are set for a 10-year term.
Key Highlights
- West Pharma and Daikyo Seiko renewed key agreements.
- Entered Amended and Restated Technology Exchange and Crosslicense Agreement.
- Also signed two Distributorship Agreements, effective July 14, 2026.
- West maintains a 49% ownership interest in Daikyo.
- Crosslicense facilitates joint development and licensing of pharmaceutical components.
- West is exclusive distributor of Daikyo products in all countries other than Japan.
- Daikyo is non-exclusive distributor of West products in Japan.
- All renewed agreements have a 10-year term.
Price Impact
More from WST
Management ChangeJun 1, 4:32 PM
West Pharma Appoints Michel Lagarde as New CEO, Effective Aug 31
CybersecurityMay 20, 4:09 PM
West Pharmaceutical fully operational after cyberattack; no material financial impact
CybersecurityMay 11, 5:12 PM
West Pharmaceutical Services Reports Material Cybersecurity Attack